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significance and clinical validity
ARIE J. VAN WINKELHOFF & EDWIN G. WINKEL
For over a century the medical profession has
employed clinical microbiology as a tool in the
diagnosis and treatment planning of infectious dis-
eases. The identification of etiologic agents helps
select the optimal drug therapy to support the patient
in overcoming an infectious disease. Clinical micro-
biology in dentistry is used in cariology, implant
dentistry, and periodontics. Recently, microbiology
as a diagnostic tool in periodontics was evaluated,
with the emphasis on sampling methods and differ-
ent techniques to detect and quantify target bacteria
(29). The present article discusses the rationale for
applying clinical periodontal microbiology in the
treatment of severe types of destructive periodontal
disease. Microbiological analysis is useful when the
information has the potential to direct clinicians to-
wards more effective treatment strategies. The con-
cepts presented here are based on the periodontal
literature as well as experience in the field of clinical
microbiology as it has existed in the Netherlands for
over 15 years. The scientific literature will be used
with the proviso that data can be interpreted in dif-
ferent ways and may sometimes result in opposite
conclusions. In addition, the scientific basis for a
rational use of clinical microbiology in periodontics is
still incomplete. However, it is the opinion of these
authors that the available information is sufficient to
support the use of clinical microbiology in perio-
dontal diagnosis and treatment planning. Since the
use of microbial testing in periodontics is to a large,
but not exclusive, extent related to the use of anti-
biotics, this paper will mostly focus on that rela-
tionship.
The discussion in this paper is based on the fol-
lowing views:
• periodontitis is a collection of etiologically differ-
ent diseases;
• there is growing evidence that some periodontal
pathogens have characteristics of exogenous
microorganisms;
• microbiological testing can help select patients
who are likely to benefit from systemic antimicro-
bial therapy;
• clinical microbiology in periodontics can contrib-
ute to cost-effective treatment.
Three basic steps in periodontics
The three main phases in periodontics include diag-
nosis, active anti-infective (cause-related) treatment,
and restorative periodontal and dental procedures
(53) (Fig. 1).
Diagnosis
Diagnosis assists in the selection of the most appro-
priate treatment based on individual treatment needs
and takes into account individual risk factors such as
smoking, stress, systemic diseases, and immuno-
competence. Past and current medication for oral
and nonoral disorders is checked. A detailed analysis
of the dental status and the degree of periodontal
destruction is also established. The patient’s view on
treatment needs completes the diagnostic phase. A
microbial diagnosis in the diagnostic phase is
sometimes desirable to assess the type and degree of
therapeutic intervention.
Infection control
The anti-infectious approach in the active perio-
dontal treatment phase consists of a number of
measures to reduce the total bacterial load. Initial
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treatment comprises supra- and subgingival debri-
dement and instruction in proper oral self-care. A
systemic or local antimicrobial therapy may be ini-
tiated after completion of the initial periodontal
treatment. To further reduce the subgingival bacterial
load, periodontal surgery may be performed. At the
end of the active periodontal treatment phase,
the recall interval for periodontal maintenance is
determined. A microbial analysis of the subgingival
microflora at the end of the active treatment phase to
test for remaining pathogens may help evaluate the
efficacy of the anti-infectious measures and assist in
determining recall frequency.
Restoration
Restoration is an important third treatment step in
periodontics. In this phase, guided tissue or bone
regeneration with barrier membranes may be used to
restore part of the lost periodontal tissue. Biological
active molecules to regain alveolar bone may be
applied. To compensate for lost teeth, dental im-
plants may be installed. It seems essential to perform
restorative procedures only after periodontal health
has been restored in the active treatment phase.
Violating this rule may jeopardise planned restorative
procedures due to recurrent infection. A microbio-
logical analysis may guide the treatment of persistent
infections prior to and after the completion of the
restorative intervention (e.g. peri-implantitis, abscess
formation).
Do we need microbiological
information to treat infectious
diseases?
In medicine, clinical microbiology is used for diag-
nosis and treatment planning.
Laboratory testing is only meaningful when the
acquired information helps to direct treatment
planning and when it assists in providing optimal
therapy. However, the majority of medical infections
are treated without any microbiological testing
because the likelihood of having a known pathogen
in a given type of infection is often high, and
experience shows that a standard antimicrobial
therapy is effective in the majority of such patients.
For instance, since Escherichia coli causes approxi-
mately 85% of uncomplicated urine tract infection,
and this pathogen is susceptible to a number of
antibiotics, microbial testing is not a prerequisite to
initiate antibiotic treatment. However, when the
standard antibiotic regimen is clinically ineffective, in
cases with infectious complications, or in recurrent
disease, changes in treatment necessitate additional
microbiological information. This approach to
infectious disease management is used in relatively
mild and uncomplicated medical infections, such as
otitis media, upper respiratory infection, eye infec-
tions, etc.
In severe and potentially life-threatening infections
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Fig. 1. Three basic steps in periodontics.
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microbial testing is an essential part of the diagnosis.
For instance, the clinical diagnosis of severe pul-
monary infection is simple and relatively easy to
obtain, but a number of viruses as well as
Mycobacterium tuberculosis, Legionella pneumophila,
Haemophilus influenzae, Klebsiella pneumoniae,
and various gram-positive bacteria including
streptococci and staphylococci can cause the
disease. It can be of critical importance to deter-
mine the etiology in specific cases of pneumonia in
order to select the optimal antimicrobial therapy.
The bacterial component of
periodontitis
The etiology and pathogenesis of periodontitis is
much better understood now than a decade ago,
and new risk factors are continually been identified.
Several risk factors are very difficult (smo-
king, stress) or impossible to control (age, genetic
traits).
Since bacteria cause gingivitis, periodontitis, and
periodontal abscesses, periodontal treatment is
aimed primarily at reducing the total periodontal
bacterial load (supra- and subgingival plaque) and
suppressing or eliminating certain target microor-
ganisms from subgingival areas. Although gram-
negative anaerobic rods and spirochetes dominate
the subgingival microbiota of most periodontitis
patients, it has become clear that marked qualitat-
ive and quantitative microbial differences exist
among patients (14, 17, 21, 24, 38, 40, 47). Factors
that influence the composition of the subgingival
microbiota include age, poor oral hygiene, tobacco
smoking, stress, systemic diseases, decreased
immunocompetence (neutropenia), and genetic
traits (20, 24, 32, 40, 47). The rate of periodontal
disease progression is not necessarily determined
by the same set of risk factors in each patient, and
a relationship probably exists between different risk
factors and various infectious agents. For example,
in severe nonsmoker periodontitis patients, a rela-
tionship seems to exist between the carrier state of
allele* 2 in both pro-inflammatory and the anti-
inflammatory interleukin 1 genes, and the absence
of Actinobacillus actinomycetemcomitans and Por-
phyromonas gingivalis (24). Despite these subjects
suffering from severe periodontitis, they lacked all
known risk factors (nonsmokers, no diabetes mell-
itus, no putative exogenous periodontal pathogens),
and their subgingival microbiota consisted of com-
mensal periodontal pathogens.
Do we need clinical microbiology
in periodontics?
Microbiological testing is not necessary to diagnose
the mere existence of gingivitis and periodontitis.
Microbiological tests are not needed to confirm what
a dental probe can easily reveal. Microbiological
knowledge can, however, be helpful in the context of
periodontal therapy. The primary approach to the
treatment of periodontitis is mechanical debride-
ment with or without periodontal surgery. Basic
periodontal treatment has been shown to be suc-
cessful in arresting the disease activity in the
majority of adult patients with chronic periodontitis
(6), especially when combined with good mainten-
ance care (3, 4). A poor treatment response, some-
times referred to as refractory periodontitis, may
occur in patients with aggressive periodontitis. The
prevalence of refractory periodontitis is difficult to
determine because different definitions of the con-
dition are used and many different treatment pro-
tocols are applied. Disease activity can recur in
maintenance patients. For some types of periodon-
titis, such as juvenile periodontitis, the disease may
recur in up to 25% of patients within 1 year fol-
lowing active therapy (25). A. actinomycetemcomi-
tans has been identified as a microbial risk factor for
poor treatment response, and a persistence of the
organism is associated with disease recurrence in
localized juvenile periodontitis (15). A poor treat-
ment response in adults with periodontitis has also
been related to a number of bacterial species. For
instance, the persistence of A. actinomycetemcomi-
tans, P. gingivalis and Tannerella forsythia (formerly
Bacteroides forsythus) after mechanical periodontal
debridement has been associated with only moder-
ate improvement in gingival bleeding on probing,
probing pocket depth, and clinical attachment level
(39, 45, 59) and with further loss of alveolar bone
height (14). Ongoing periodontal attachment loss in
maintenance patients has been related to the per-
sistence of, among others, P. gingivalis, Prevotella
intermedia, and A. actinomycetemcomitans (16, 56).
Available evidence thus shows that certain microbial
complexes are associated with a poor treatment re-
sponse and ongoing or recurrent periodontal disease
activity in susceptible patients. Refractory perio-
dontitis patients may benefit from microbiological
testing to identify the presence and levels of bacteria
that could be a target for further treatment, especi-
ally when considering adjunctive systemic antibiotic
therapy.
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Endogenous vs. exogenous periodontal
pathogens
Most cultivable subgingival bacterial species in
periodontitis are part of the normal oral microflora.
Common oral bacterial species accumulate in the
subgingival area and, over time, may constitute a
significant part of subgingival plaque. Periodontitis
associated with commensal periodontal bacteria may
be considered a commensal or opportunistic infec-
tion. It is questionable whether A. actinomycetem-
comitans and P. gingivalis are part of the normal
periodontal microflora (for review see [44]). Both
species have the characteristics of exogenous patho-
gens rather than of opportunistic pathogens (18).
This presumption is partly based on the finding that
both species exhibit a low occurrence in periodon-
tally healthy subjects, related to Koch’s first postulate
of causality. The concept of exogenous periodontal
bacteria has gained strength as a result of recent
studies. Griffen et al. (19) used a sensitive polymerase
chain reaction technique to detect P. gingivalis in
adult patients with periodontitis and in periodontally
healthy subjects. They concluded that, based on the
low prevalence in periodontal health, P. gingivalis is
not a member of the normal periodontal microflora.
In a similar study, using anaerobic culture tech-
niques, van Winkelhoff et al. (50) confirmed the low
occurrence of P. gingivalis in periodontally healthy
subjects (10.6%) and found a strong association of
this pathogen with destructive periodontal disease
(OR ¼ 12.3). A. actinomycetemcomitans was detected
in only 12.8% of the subjects without periodontitis
(50). Boutaga et al. (9) applied a sensitive real-time
polymerase chain reaction technique to detect
P. gingivalis and A. actinomycetemcomitans in peri-
odontal health and disease and found the prevalence
of P. gingivalis and A. actinomycetemcomitans in
periodontal health to be only 10% and 18%,
respectively. The subgingival prevalence of A. actino-
mycetemcomitans and P. gingivalis seems related to
age and treatment history, as A. actinomycetemcom-
itans tends to decrease and P. gingivalis to increase
with increasing age in periodontitis patients (40).
Indeed, A. actinomycetemcomitans and P. gingivalis
may be considered true infectious agents in the
human oral cavity (Fig. 2). This concept has clinical
implications as it allows for a differentiated treatment
















Fig. 2. Different periodontal infections on the basis of the origin of the pathogens.
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strategy: endogenous pathogens may merely need to
be reduced in subgingival sites, whereas exogenous
pathogens usually should and can be eliminated from
infected subjects (51). It should also be noted that
data on the prevalence of periodontal pathogenic
bacteria are based mainly on studies of western
populations and may be not pertain to different
ethnic groups (41, 46). So far, however, there are no
data to show that pathogens behave differently in
different ethnic populations (45). In an Indonesian
population, Timmerman et al. (46) showed that
A. actinomycetemcomitans is a periodontal disease
susceptibility factor and that P. gingivalis is associ-
ated with periodontal disease progression.
Relationship between
microorganisms and the outcome
of periodontal treatment
A. actinomycetemcomitans and P. gingivalis cannot
be removed from a significant part of deep perio-
dontal lesions by mechanical therapy alone (for
review see [44]), as demonstrated in localized juvenile
periodontitis (15, 52) and in adult periodontitis
patients (39, 40, 59). The percentage of A. actinomy-
cetemcomitans and P. gingivalis may even increase
following scaling and root planing (33, 39). Chaves
et al. (14) showed that periodontal lesions with
detectable P. gingivalis at 1, 3 and 6 months after
debridement showed further alveolar bone loss,
whereas lesions without this pathogen at any time
point post-treatment tended to show alveolar bone
gain (Fig. 3). The subgingival persistence of T. forsy-
thia has also been associated only with a moderate
improvement in clinical periodontal status (45, 59).
Incomplete removal of certain subgingival pathogens
is related to initial probing pocket depth (33, 35), the
location of the lesion, the anatomy of the tooth (30),
compliance with instructions for oral home care (32),
and possibly the immunocompetence of the patient
(20).
Are specific pathogens predictors
of further periodontal attachment
loss?
There are sufficient data to support the important
role of specific periodontal bacteria in progressive
periodontitis of treated patients. In one study, adult
patients with refractory periodontitis were investi-
gated clinically and microbiologically at baseline and
at 12 months’ post-treatment (56). Periodontal
lesions without detectable A. actinomycetemcomi-
tans, P. gingivalis, or P. intermedia showed no fur-
ther clinical attachment loss, whereas 20% of sites
with detectable levels of one or more of these path-
ogens experienced ‡ 2 mm additional attachment
loss (56). In a 5-year follow-up study, only perio-
dontal pockets without detectable A. actinomyce-
temcomitans or P. gingivalis and < 5% P. intermedia
–0.6 –0.5 –0.4 –0.3 –0.2 –0.1 0 0.1
Pg - 1,3 or 6 mo




– 1,3 or 6 mo




Bone height change (mm)
Fig. 3. Presence of P. gingivalis (Pg) and bone height change 1, 3, and 6 months after initial periodontal treatment (data
from [14]).
44
van Winkelhoff & Winkel
remained stable, whereas 67% of sites testing positive
for one or more of these species lost attachment (16).
Longitudinal and retrospective studies from various
laboratories have also indicated an increased risk for
periodontal breakdown in sites positive for specific
periodontal pathogens (10, 12, 21, 38, 42, 43).
According to Machtei et al. (31), periodontitis pa-
tients with detectable T. forsythia at baseline had
more deteriorating sites and twice as much tooth
mortality as patients without this pathogen. Risk
factors for incomplete removal of periodontal path-
ogens may be smoking, poor oral hygiene level, and
insufficient scaling and root planing. One criterion
for the end-point of periodontal treatment is sup-
pression of certain bacterial pathogens to below the
level of detection. Clinical periodontal microbiology
can play a role in designing effective therapies and in
monitoring treatment efficacy (2).
Systemic antibiotics
Antibiotics can kill or inactivate bacteria that are
inaccessible to periodontal instrumentation, they can
enhance the effects of mechanical periodontal treat-
ment, they can reduce the risk for refractory or
recurrent disease, and they can reduce the number of
teeth that need periodontal surgery. One strategy of
antibiotics in periodontics is to use these drugs on
the basis of clinical need. This approach is sometimes
employed for severe periodontitis at a young age or
for certain clinical conditions such as angular bony
defects and suppuration. Other reasons for consid-
ering systemic antimicrobial treatment may be
poor treatment response after initial periodontal
treatment, expressed as only a moderate pocket
reduction, little or no attachment gain, or a high
percentage of residual bleeding sites despite good
oral hygiene compliance.
There is a body of evidence suggesting that, when
used as adjuncts to mechanical treatment, systemic
antibiotics can significantly improve periodontal
treatment outcome (8, 26, 44, 51, 57, 58). Members of
the 4th European Workshop on Periodontology pro-
duced a systemic review on the effects of systemic
antibiotic therapies as adjuncts to mechanical peri-
odontal treatment in periodontitis patients. Meta-
analyses revealed that treatment with spiramycin,
metronidazole and metronidazole plus amoxicillin
significantly improved the effect of scaling and root
planing compared to controls and placebo-treated
patients (22). However, those studies did not use the
microbial composition of the subgingival plaque as a
selection criterion for antibiotic therapy, and the
choice of antimicrobial therapy was empiric and
based on the experience of the clinician. Such
approach does not consider the possibility that some
pathogens may display resistance to the tested drugs.
This may occur for A. actinomycetemcomitans, which
is not susceptible to metronidazole when used as a
mono-therapy. Therefore, clinical studies carried out
without selecting antibiotics on the basis of microbial
variables may underestimate the potential effective-
ness of periodontal systemic antibiotic therapy.
A more targeted approach to periodontal antibiotic
therapy is microbiological analysis of the subgingival
microflora to determine the presence and levels of
periodontal pathogens. The decision whether or not
to prescribe a systemic antimicrobial treatment and
subsequently the choice of an antibiotic is then based
on the microbiological outcome of the analysis (2).
This approach has several advantages.
Culturing of subgingival key pathogens opens the
possibility of antibiotic susceptibility testing that can
provide information on the most optimal antibiotic
choice and regimen. The selected antimicrobial ther-
apy can be based on known susceptibility profiles of
the target microorganisms and on documented
effectiveness in the periodontal literature. For
example, clindamycin generally is not effective
against A. actinomycetemcomitans and consequently
will fail to eradicate or significantly suppress this
pathogen in infected periodontal sites. Patients with
high levels of beta-lactamase producing bacteria may
not benefit from unprotected amoxicillin therapy
(23, 53).
Patients who are unlikely to benefit from systemic
antimicrobial therapy can be excluded. Periodontitis
patients testing positive for P. gingivalis and
A. actinomycetemcomitans at baseline seem to be
prime candidates for adjunctive systemic antibiotic
treatment. Flemmig et al. (17) showed that systemic
metronidazole plus amoxicillin treatment following
scaling and root planing was only effective in
A. actinomycetemcomitans-infected patients. In the
absence of A. actinomycetemcomitans, adjunctive
antibiotic therapy showed no clinical benefit over
scaling and root planing alone. This important
observation indicates that microbiological selection
of patients positive for A. actinomycetemcomitans is
clinical relevant and overtreatment with antibiotics
can be prevented by excluding subjects without this
pathogen. Winkel et al. (57) used a double-blind
placebo-controlled randomized protocol to investi-
gate the clinical and microbiological effects of met-
ronidazole plus amoxicillin. In that study, patients
45
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were not selected on the basis of microbiological
parameters, i.e. microbial analysis of the subgingival
plaque was also performed blindly (57). Probing
pocket depth reduction, clinical attachment gain, and
reduced bleeding on probing occurred more often in
patients receiving antibiotic medication than in pla-
cebo-treated subjects. Further analysis showed that
the additional clinical effects of the antibiotics in
terms of probing pocket depth reduction (Fig. 4)
and reduction in the number of pockets ‡ 5 mm
(Fig. 5) could be attributed to patients who were
culture-positive for P. gingivalis at baseline. P. gin-
givalis-negative subjects at baseline treated with
metronidazole plus amoxicillin showed no significant
improvements in pocket depth and in number of
sites with probing depth ‡ 5 mm compared to pla-
cebo-treated subjects. These observations are evi-
dence that antibiotic treatment as an adjunct to
mechanical debridement benefits a select group of
periodontitis patients, and support the notion that
microbiological testing prior to antibiotic therapy is a
rational diagnostic approach in periodontics.
The over- and misuse of antibiotics can be reduced,
thereby not contributing to the increasing problem of
antimicrobial resistance. Apart from clinical and
microbiological arguments for the selective use of
systemic antimicrobial therapy in periodontics, there
is the global problem of emerging antimicrobial
resistance among human pathogens. Uncontrolled
use, misuse and poor compliance are major causes of
the growing phenomenon of microbial resistance,
which poses a serious challenge in the control of
infectious diseases and threatens public health in
developed and underdeveloped countries. For
instance, antimicrobial resistance of Streptococcus
pneumoniae to penicillin is correlated with the local
use of beta-lactam antibiotics and macrolides (11).
Emerging antimicrobial resistance has also been
noted for periodontal bacteria. The level of resistant
periodontal bacteria towards beta-lactam antibiotics,
metronidazole, clindamycin, and tetracycline was
found to be significantly higher in periodontitis
patients in Spain than in the Netherlands (49). This
finding could be related to a significant higher intake
of antibiotics in Spanish patients. In a study of anti-
biotic use in European countries, Cars et al. (13)
found a great variation in antibiotic consumption
among various countries. The use of antibiotics was
significantly higher in Mediterranean countries than
in other European countries. The Netherlands was
the country with the lowest antibiotic use and France
and Spain the countries with the highest (Fig. 6).
Restricted and controlled use and improved compli-
ance seem to be the best strategies to overcome the
problem of antimicrobial resistance. Therefore, to
limit medication to patients most likely to benefit
from the therapy, prescription of antibiotics in peri-
odontal patients should be based on defined clinical
and microbiological parameters rather than on an
empiric approach to prescription. Also, the institu-
tion of antibiotic regimens without scientifically
demonstrated clinical effects should be avoided.
Selection of effective antibiotics at the time of initial
therapy will contribute to a cost-effective treatment.
Microbiological testing prior to systemic antimicro-
bial treatment will prevent unnecessary use of anti-
biotics, thereby reducing the costs of medication and
also of the overall treatment (17, 57). There is evi-
dence that optimal use of antibiotics reduces the total
number of teeth in need of surgical intervention (28,
57). In contrast, repeated root debridement in
patients with ongoing disease activity is time-con-
suming and costly, and is often ineffective (5). In
addition, there are potentially unwarranted effects of
repeated periodontal mechanical treatment, such as












Fig. 4. Change in full-mouth pocket probing depth (PPD)
in P. gingivalis (Pg)-infected and noninfected patients at
baseline after metronidazole plus amoxicillin (T) or pla-








Pg neg-P Pg neg-T Pg pos-P Pg pos-T
%
P < 0.001
Fig. 5. Mean reduction in percent sites with probing
pocket depth ‡5 mm in P. gingivalis (Pg)-infected and
noninfected patients at baseline after metronidazole plus
amoxicillin (T) or placebo (P) medication (data from [57]).
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Practical aspects
Microbiological sampling
The topic of microbiological sampling has been
discussed recently (29). A practical and economic
approach to sample major pathogens from the sub-
gingival area is to pool samples from the deepest
bleeding pockets of molar teeth in each quadrant
(34). A sampling strategy based on site-specific
information is of less importance as a precursor for
systemic antibiotic therapy.
Types of microbial tests
The culture technique represents an open test system
and allows the detection and quantification of all
cultivable bacterial species. It also enables the
detection of unusual pathogens and superinfecting
organisms, such as Candida species, staphylococci,
enterococci and other enteric organisms, which may
occur in medically compromised patients and after
unsuccessful systemic periodontal antibiotic therapy.
Antibiotic susceptibility testing can only be applied
after cultivation and isolation of target species.
Polymerase chain reaction techniques have been
developed to detect periodontal pathogens and
results of these tests are in agreement with culture
results (9).
Microbial testing
Testing before active periodontal treatment. Patients
suffering from aggressive periodontitis run the risk
of continuing periodontal disease activity after
mechanical depuration and can benefit from
microbial testing prior to initial treatment. Most
aggressive periodontitis patients show significantly
improved healing after systemic antibiotic treat-
ment.
Control testing after active treatment. Because a
marked suppression of periodontal pathogens is
associated with periodontal stability (8, 14, 16, 37,
56), microbial testing can assist in determining the
endpoint of periodontal treatment and in estab-
lishing the length of the recall interval. Control
microbiological testing may especially be opportune
in patients scheduled for implant dentistry to
assure that major periodontal pathogens have been
eradicated and commensal bacteria have been















































































Fig. 6. Daily dose of antibiotics per 100,000 inhabitants in different countries of the European Union (data from [13]).
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Refractory periodontitis. Subjects with refractory
periodontitis are a group of patients who can benefit
from microbial testing and subsequent antibiotic
therapy. The diagnosis of refractory periodontitis
should be reserved for patients who experience little
reduction in bleeding on probing and pocket depth
despite diligent mechanical debridement and excel-
lent oral hygiene. Continuing suppuration may also
constitute a sign of ongoing active disease.
Maintenance patients. The aim of regular main-
tenance therapy is to interfere with the recolonization
of subgingival sites by potentially pathogenic bac-
teria. Patients with recurrent disease activity in the
maintenance phase may benefit from re-treatment
by scaling and root planing, reinforcement of oral
hygiene measures, periodontal surgery or local
application of an antimicrobial agent. Microbial
testing in these cases can be performed as needed.
Patients with recurrent periodontal disease
associated with A. actinomycetemcomitans and ⁄or
P. gingivalis or high levels of T. forsythia may benefit
from antibiotic treatment.
Figure 7 presents a practical approach to microbial
testing and the use of antibiotics in patients with
severe types of periodontitis.
Microbiological considerations for
sequencing of antibiotics
Antimicrobial agents can be used at different times
in the active treatment phase. A large number of
clinical studies have employed antibiotics during the
initial treatment phase. However, there are micro-
biological arguments that speak for the use of sys-
temic antibiotics after the completion of initial
treatment.
• Antibiotics work best when the supragingival pla-
que level is low. Low plaque levels are typically

















Fig. 7. Flow chart of microbial testing and the use of antibiotics.
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• Antibiotics work best when the subgingival bac-
terial load has been significantly reduced by
mechanical debridement (inoculum effect). In
particular, a reduction of the commensal (endo-
genous) microflora should be attempted.
• Mechanical treatment can disrupt the bacterial
biofilm on the root surface, which may increase the
effectiveness of antimicrobial agents against resi-
dent bacteria. Loesche et al. (27) demonstrated
that systemic metronidazole therapy is clinically
more effective when delivered after mechanical
debridement than during the mechanical treat-
ment phase. Use of potent antibiotics without
thorough mechanical debridement and without
proper oral hygiene measures should be regarded
as improper (2).
• To reduce the oral load of periodontal pathogens,
teeth with a poor prognosis may be extracted prior
to an antibiotic therapy.
Antimicrobial regimens
Microbial analysis of the subgingival microflora in
periodontitis allows a differentiated choice of sys-
temic antibiotics. Table 1 lists antibiotic regimens
against some marker bacteria. Several antibiotics
have predictable effects on target organisms. Met-
ronidazole is effective against P. gingivalis, P. inter-
media, and most other gram-negative anaerobic rods.
Amoxicillin acts against a wide range of subgingival
bacteria but may, unprotected, be inactivated by
beta-lactamases (23, 54). Clindamycin and tetracy-
clines also have broad spectra of activity on the
subgingival microflora. Predictable suppression of
subgingival A. actinomycetemcomitans requires
metronidazole plus amoxicillin or other combina-
tions of antibiotics (51).
It should also be noted that antibiotic regimens
used in many clinical trials are not necessarily those
that will display the optimal effect in daily practice.
Based on 20 mgÆkg)1Æday)1 body weight, a daily dose
of 750 mg of metronidazole can only treat an adol-
escent of 40 kg. In adults, a dose of 1500 mgÆday)1 is
indicated (55).
Parameters that determine the dosage of an anti-
microbial agent include:
• susceptibility of the pathogen(s);
• severity of the infection;
• body mass (standard dose should adjusted for
under- and overweight patients);
• other medications.
Smokers with periodontitis may benefit from pro-
longed medication time since smoking decreases the
gingival blood flow and the amount of crevicular
fluid, and thereby the exposure of subgingival path-
ogens to systemic antibiotics (36).
Table 1. Antibiotic regimens against marker bacteria
Indication Antimicrobial therapy Usual dosage Reference






Clindamycin 300 mg qid 7–8 days 22
Nonspecific infection Doxycycline
Spiramycin
100–200 mg 1 · day 7–14 days
1.0 g bid 7 days
1, 7
A. actinomycetemcomitans or





375–500 mg tid, both 7 days





















Microbial analysis in periodontics aims to:
• discriminate between different microbial types of
periodontal infections;
• select subjects likely to benefit from adjunct sys-
temic antimicrobial therapy;
• assist in selecting the most appropriate antibiotic
treatment in accordance with the composition of
the subgingival microflora;
• contribute to minimizing overuse of potent anti-
microbial agents and the emergence of antimi-
crobial resistance;
• screen for horizontal and vertical transmission of
periodontal pathogens among family members;
• help to determine the endpoint of active perio-
dontal treatment and to establish the recall interval
for periodontal maintenance care;
• help select patients in need for periodontal
treatment before inserting implants in partially
edentulous subjects. This may especially be indi-
cated in subjects with a history of periodontitis
(48).
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